MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- NATCO PHARMA LIMITED (pharmaceuticals)
- NATCO PHARMA LIMITED Financial Data
Natco Pharma Fact Sheet (NTPH)
Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
NATCO PHARMA Price History
| % ch | % | 3.7 |
| No. of shares | m | 166.15 |
| % ch week | % | 3.8 |
| % ch 1-mth | % | -16.5 |
| % ch 12-mth | % | -8.1 |
| 52 week H/L | Rs | 737.8/450.0 |
NATCO PHARMA Financials
| No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
|---|
| NATCO PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 2,291 | 624 | 849 | 1,080 | 849 | |
| Low | Rs | 656 | 366 | 418 | 671 | 557 | |
| Sales per share (Unadj.) | Rs | 248.4 | 327.8 | 578.9 | 592.1 | 573.8 | |
| Earnings per share (Unadj.) | Rs | 37.6 | 43.5 | 138.9 | 188.4 | 176.0 | |
| Diluted earnings per share | Rs | 7.5 | 9.1 | 29.2 | 41.8 | 38.7 | |
| Cash flow per share (Unadj.) | Rs | 51.8 | 58.2 | 154.5 | 206.3 | 198.2 | |
| Dividends per share (Unadj.) | Rs | 5.00 | 1.25 | 6.75 | 8.25 | 6.25 | |
| Adj. dividends per share | Rs | 1.00 | 0.26 | 1.42 | 1.83 | 1.37 | |
| Dividend yield (eoy) | % | 0.3 | 0.3 | 1.1 | 0.9 | 0.9 | |
| Book value per share (Unadj.) | Rs | 254.6 | 372.8 | 473.8 | 833.6 | 842.7 | |
| Adj. book value per share | Rs | 50.9 | 78.1 | 99.5 | 185.1 | 185.1 | |
| Shares outstanding (eoy) | m | 33.23 | 34.83 | 34.90 | 36.90 | 36.50 | |
| Bonus/Rights/Conversions | - | IS | IS | IS | BB | ||
| Price / Sales ratio | x | 5.9 | 1.5 | 1.1 | 1.5 | 1.2 | |
| Avg P/E ratio | x | 39.2 | 11.4 | 4.6 | 4.6 | 4.0 | |
| P/CF ratio (eoy) | x | 28.4 | 8.5 | 4.1 | 4.2 | 3.5 | |
| Price / Book Value ratio | x | 5.8 | 1.3 | 1.3 | 1.1 | 0.8 | |
| Dividend payout | % | 13.3 | 2.9 | 4.9 | 4.4 | 3.6 | |
| Avg Mkt Cap | Rs m | 48,963 | 17,230 | 22,116 | 32,311 | 25,660 | |
| No. of employees | `000 | 3.1 | 1.3 | 4.4 | 4.8 | 5.0 | |
| Total wages/salary | Rs m | 1,369 | 1,867 | 2,432 | 3,256 | 3,559 | |
| Avg. sales/employee | Rs Th | 2,647.7 | 8,462.6 | 4,579.9 | 4,522.5 | 4,225.3 | |
| Avg. wages/employee | Rs Th | 439.3 | 1,383.8 | 551.3 | 674.0 | 718.0 | |
| Avg. net profit/employee | Rs Th | 400.8 | 1,124.2 | 1,099.3 | 1,439.0 | 1,295.9 | |
| NATCO PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 8,253 | 11,416 | 20,202 | 21,848 | 20,945 | |
| Other income | Rs m | 149 | 108 | 139 | 404 | 1,302 | |
| Total revenues | Rs m | 8,402 | 11,524 | 20,341 | 22,252 | 22,247 | |
| Gross profit | Rs m | 2,100 | 2,640 | 6,834 | 9,284 | 7,948 | |
| Depreciation | Rs m | 473 | 510 | 544 | 662 | 810 | |
| Interest | Rs m | 317 | 229 | 185 | 154 | 193 | |
| Profit before tax | Rs m | 1,459 | 2,009 | 6,244 | 8,872 | 8,247 | |
| Minority Interest | Rs m | -44 | -14 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | -151 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 15 | 479 | 1,395 | 1,920 | 1,823 | |
| Profit after tax | Rs m | 1,249 | 1,517 | 4,849 | 6,952 | 6,424 | |
| Gross profit margin | % | 25.4 | 23.1 | 33.8 | 42.5 | 37.9 | |
| Effective tax rate | % | 1.0 | 23.9 | 22.3 | 21.6 | 22.1 | |
| Net profit margin | % | 15.1 | 13.3 | 24.0 | 31.8 | 30.7 | |
| NATCO PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 4,830 | 8,323 | 10,873 | 21,307 | 23,472 | |
| Current liabilities | Rs m | 4,137 | 4,929 | 6,265 | 5,920 | 7,287 | |
| Net working cap to sales | % | 8.4 | 29.7 | 22.8 | 70.4 | 77.3 | |
| Current ratio | x | 1.2 | 1.7 | 1.7 | 3.6 | 3.2 | |
| Inventory Days | Days | 97 | 114 | 63 | 73 | 92 | |
| Debtors Days | Days | 85 | 84 | 86 | 107 | 88 | |
| Net fixed assets | Rs m | 8,389 | 9,253 | 11,693 | 14,986 | 18,648 | |
| Share capital | Rs m | 332 | 348 | 349 | 369 | 365 | |
| "Free" reserves | Rs m | 7,945 | 12,373 | 16,144 | 30,353 | 34,525 | |
| Net worth | Rs m | 8,461 | 12,983 | 16,534 | 30,760 | 30,760 | |
| Long term debt | Rs m | 970 | 0 | 0 | 0 | 0 | |
| Total assets | Rs m | 13,840 | 18,238 | 23,176 | 37,151 | 43,031 | |
| Interest coverage | x | 5.6 | 9.8 | 34.8 | 58.6 | 43.7 | |
| Debt to equity ratio | x | 0.1 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.6 | 0.6 | 0.9 | 0.6 | 0.5 | |
| Return on assets | % | 11.3 | 9.6 | 21.7 | 19.1 | 15.4 | |
| Return on equity | % | 14.8 | 11.7 | 29.3 | 22.6 | 20.9 | |
| Return on capital | % | 16.8 | 17.1 | 38.9 | 29.3 | 27.4 | |
| Exports to sales | % | 34.7 | 27.5 | 0 | 0 | 0 | |
| Imports to sales | % | 6.5 | 10.2 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 2,866 | 3,141 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 538 | 1,168 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 3,156 | 3,457 | 6,793 | 10,322 | 11,536 | |
| Fx outflow | Rs m | 959 | 1,688 | 2,254 | 2,978 | 2,939 | |
| Net fx | Rs m | 2,197 | 1,769 | 4,538 | 7,343 | 8,597 | |
| NATCO PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 927 | 1,024 | 3,458 | 4,636 | 6,688 | |
| From Investments | Rs m | -1,148 | -1,755 | -2,994 | -11,155 | -6,122 | |
| From Financial Activity | Rs m | 291 | 856 | -477 | 6,509 | -509 | |
| Net Cashflow | Rs m | 22 | 117 | -7 | -18 | 66 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: V. C. Nannapaneni (MD) | COMP SEC: M. Adinarayana | YEAR OF INC: 1981 | BSE CODE: 524816 | FV (Rs): 10 | DIV YIELD (%): 0.3 |
More Pharmaceuticals Company Fact Sheets: STRIDES PHARMA SCIENCE PIRAMAL ENTERPRISES INDOCO REMEDIES TTK HEALTHCARE PANACEA BIOTECH
Compare NATCO PHARMA With: STRIDES PHARMA SCIENCE PIRAMAL ENTERPRISES INDOCO REMEDIES TTK HEALTHCARE PANACEA BIOTECH
Compare NATCO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)
Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.
Views on news
NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsMost Popular
Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)
Mar 30, 2020This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...
The Biggest Trading Opportunity of 2020 is Here...
Mar 26, 2020India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!
A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)
Mar 24, 2020Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.
One Stock that is All Charged Up for the Post Coronavirus Rebound (The 5 Minute Wrapup)
Apr 1, 2020A stock with strong moat is currently trading near 5-year lows.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
TRACK NATCO PHARMA
- Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NATCO PHARMA
NATCO PHARMA - CIPLA COMPARISON
COMPARE NATCO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.